Advanced in Wilms Tumor

Dr. Benjamin A. Teply

Oncology
Unmc Physicians
Emile 42nd St, 
Omaha, NE 
Accepting New Patients
Offers Telehealth
Advanced in Wilms Tumor
Unmc Physicians
Emile 42nd St, 
Omaha, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Benjamin Teply is an Oncologist in Omaha, Nebraska. Dr. Teply is rated as an Advanced provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, WT1-Related Wilms Tumor Syndromes, Hormone Replacement Therapy (HRT), and Tissue Biopsy. Dr. Teply is currently accepting new patients.

His clinical research consists of co-authoring 47 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Student in an Organized Health Care Education/Training Program in MI
Hospital Affiliations
Bellevue Medical Center, LLC
The Nebraska Medical Center
Languages Spoken
English
American Sign Language
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Great Plains Medicare Advantage
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 10 Less Insurance Carriers -

Locations

UNMC PHYSICIANS
Emile 42nd St, Omaha, NE 68198

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2025
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2025
Intervention Type: Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Other
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

47 Total Publications

Synovial Fluid in Checkpoint Inhibitor-Induced Inflammatory Arthritis.
Synovial Fluid in Checkpoint Inhibitor-Induced Inflammatory Arthritis.
Journal: Oncology (Williston Park, N.Y.)
Published: May 22, 2025
Similar Doctors
Distinguished in Wilms Tumor
Dr. Ralph J. Hauke
Hematology Oncology | Hematology | Oncology
Distinguished in Wilms Tumor
Dr. Ralph J. Hauke
Hematology Oncology | Hematology | Oncology

Oncology Hematology West, PC

611 Fenwick Dr, 
Papillion, NE 
 (8.7 miles away)
402-593-3141
Languages Spoken:
English, American Sign Language, Spanish
See accepted insurances
Accepting New Patients

Ralph Hauke is a Hematologist Oncology specialist and a Hematologist in Papillion, Nebraska. Dr. Hauke is rated as a Distinguished provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Melanoma, Bone Marrow Transplant, and Tissue Biopsy. Dr. Hauke is currently accepting new patients.

Distinguished in Wilms Tumor
Dr. Luke T. Nordquist
Hematology Oncology | Oncology | Hematology
Distinguished in Wilms Tumor
Dr. Luke T. Nordquist
Hematology Oncology | Oncology | Hematology

Urology Cancer Center PC

7500 Mercy Rd, 
Omaha, NE 
 (3.1 miles away)
402-398-6060
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Luke Nordquist is a Hematologist Oncology specialist and an Oncologist in Omaha, Nebraska. Dr. Nordquist is rated as an Elite provider by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, and Prostatectomy. Dr. Nordquist is currently accepting new patients.

Advanced in Wilms Tumor
Dr. Irina Popa
Hematology | Oncology
Advanced in Wilms Tumor
Dr. Irina Popa
Hematology | Oncology
8303 Dodge St, #225, 
Omaha, NE 
 (3.4 miles away)
402-354-5860
Languages Spoken:
English
See accepted insurances

Irina Popa is a Hematologist and an Oncologist in Omaha, Nebraska. Dr. Popa is rated as a Distinguished provider by MediFind in the treatment of Wilms Tumor. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Colorectal Cancer, and Hemangioma Thrombocytopenia Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Teply's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile